Immunai

New York, United States

Immunai is a biotech company that provides mapping and reprogramming immunology, machine learning, and software engineering.

Oct 2021

Series B

Top Investors

8VCCatalio Capital ManagementTLV PartnersMeron CapitalAlexandria Venture Investments

19,000+ verified contacts

Emails, phones & LinkedIn profiles

Who are Immunai's investors?

Immunai's investors include 8VC, Catalio Capital Management, TLV Partners, Meron Capital, Alexandria Venture Investments.

Where is Immunai headquartered?

Immunai is headquartered in New York, United States.

What does Immunai do?

Immunai is a biotech company that provides mapping and reprogramming immunology, machine learning, and software engineering.

What stage is Immunai at?

Immunai is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated October 27, 2021.

MLA

"Immunai — Funding & Investors." VCBacked, October 27, 2021, https://www.vcbacked.co/company/immunai. Accessed July 1, 2026.

APA

VCBacked. (2021). Immunai — Funding & Investors. Retrieved July 1, 2026, from https://www.vcbacked.co/company/immunai

Wikipedia (cite web)

{{cite web |title=Immunai — Funding & Investors |url=https://www.vcbacked.co/company/immunai |website=VCBacked |access-date=July 1, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated October 27, 2021.